FOI 25-0144 LD – Baricitinib 2 Mg Tablet

Written by Claude Haiku 4.5 from the extracted text on 27 Feb 2026. It can miss or misread redacted and scanned pages. Check the source before relying on it.

Eli Lilly Australia proposed a price reduction for baricitinib 2 mg and 4 mg tablets (Olumiant®), used to treat rheumatoid arthritis on the PBS, from $1,092.47 to $934.00 per pack effective 1 August 2024. To maintain the existing effective ex-manufacturer price while lowering the published price, a Special Pricing Arrangement rebate was negotiated. The department sought execution of a Deed of Variation formalising the rebate terms, with the specific rebate percentage redacted under section 47(1)(b). Eli Lilly had already agreed and signed the deed. The Assistant Secretary was delegated authority under Section 85E of the National Health Act 1953 to execute the agreement on behalf of the Commonwealth.